65
Republic of the Philippines Department of Health Food and Drug Administration Guidelines on the Implementation of New Rules and Regulations on the Licensing of Drug Manufacturer and its Subclass (Packer/ Repacker/ Trader) following Administrative Order No. 2014-00xx, dated xx Center for Drug Regulation and Research Media Room, 1 st Floor, Main Building Civic Drive, Filinvest Corporate City, Alabang, Muntinlupa City 17 September 2014 1

Guidelines on the Implementation of New Rules and ... Licensing...For single proprietorship - Certificate of ... • Barangay • city ... Application Form 3. Updated Site Master File

Embed Size (px)

Citation preview

Republic of the Philippines Department of Health

Food and Drug Administration

Guidelines on the Implementation of New

Rules and Regulations on the Licensing of

Drug Manufacturer and its Subclass (Packer/

Repacker/ Trader) following Administrative

Order No. 2014-00xx, dated xx

Center for Drug Regulation and Research Media Room, 1st Floor, Main Building

Civic Drive, Filinvest Corporate City, Alabang, Muntinlupa City

17 September 2014

1

Presentation Outline

A. Objectives of Meeting

B. Draft Regulation

C. Discussion

Center for Drug Regulation and Research 2

Regulation Outline

I. Rationale

II. LTO Applications

III.Exemption in Providing Another Pharmacist for Additional Licensed Activity

IV.Responsiblities of Implementing Offices

Center for Drug Regulation and Research 3

Regulation Outline

V. Transitory Provisions

VI. Repealing/Separability Clause

VII. Effectivity

VIII.Annex A: Requirements

IX. Annex B: Variations

Center for Drug Regulation and Research 4

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 5

A. OBJECTIVES OF THE MEETING

Objectives of the Meeting

Discuss the draft regulation

Gather inputs/suggestions from stakeholders

Test run the proposed forms for application

Center for Drug Regulation and Research 6

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 7

B. DRAFT REGULATION

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 8

RATIONALE

Manufacturer Regulation

Rationale

requirements for the applications for initial and renewal issuance of License to Operate (LTO), variations, as well as other guidelines relevant to these establishments

Center for Drug Regulation and Research 9

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 10

LTO APPLICATION

Manufacturer Regulation

A. Documentary Requirements

(1) Application Form

Completely filled-up

signed by the authorized personnel

duly notarized

Center for Drug Regulation and Research 11

A. Documentary Requirements

(2) Proof of Business Name Registration

For single proprietorship - Certificate of Business Registration issued by DTI

For corporation, partnership and other juridical person - Certificate of Registration issued by SEC and Articles of Incorporation

Center for Drug Regulation and Research 12

A. Documentary Requirements

(2) Proof of Business Name Registration

For cooperative - Certificate of Registration issued by the Cooperative Development Authority and the approved by-laws

For government-owned or controlled corporation - the law highlighting the provision creating such establishment

Center for Drug Regulation and Research 13

A. Documentary Requirements

(2) Proof of Business Name Registration

Must specify exact and complete address, where applicable:

Center for Drug Regulation and Research 14

• unit number • Floor • Building • Lot • Block

• street • Phase • Barangay • city/ municipality • province

A. Documentary Requirements

(3) Credentials of pharmacist and other qualified personnel

For pharmacist

• Valid PRC ID

• Certificate of Attendance to Licensing Seminar

Center for Drug Regulation and Research 15

A. Documentary Requirements

(3) Credentials of pharmacist and other qualified personnel

For other qualified personnel

• CV

• Training records to prove qualification

Center for Drug Regulation and Research 16

A. Documentary Requirements

(3) Credentials of pharmacist and other qualified personnel

Qualified personnel

• production manager

• quality assurance manager

• quality control manager

• authorized person for batch release

Center for Drug Regulation and Research 17

A. Documentary Requirements

(4) Risk Management Plan

Details on:

• identify, characterize, prevent or minimize risk

• PV activities and interventions to manage risks

Center for Drug Regulation and Research 18

A. Documentary Requirements

(5) Location Plan

• Sketch of the location

• “how to get there”

• Directions with landmarks

• GPS Coordinates

Center for Drug Regulation and Research 19

A. Documentary Requirements

(6) Site Master File

• Based on PIC/s GMP

Center for Drug Regulation and Research 20

A. Documentary Requirements

(7) Proof of Payment

• OR or payment slip

Center for Drug Regulation and Research 21

A. Documentary Requirements

(8) Self-assessment Toolkit

Center for Drug Regulation and Research 22

B. Evaluation and Compliance to cGMP

(1) Desktop Evaluation

• Initially reviewed by regional offices to determine compliance with Admin and tech reqts

Center for Drug Regulation and Research 23

B. Evaluation and Compliance to cGMP

(2) Inspection

In addition to the submitted application, the following documents will be verified during inspection:

• QMS

• Quality manual and SOPs

• Contract agreements

• Reference materials

Center for Drug Regulation and Research 24

B. Evaluation and Compliance to cGMP

(2) Inspection

a)Pre-opening inspection

b) Post-licensing inspection

• Routinely done

• maV may require

• Subject to regulatory action

Center for Drug Regulation and Research 25

B. Evaluation and Compliance to cGMP

(2) Inspection

Preliminary report shall be issued to the establishment after inspection

Center for Drug Regulation and Research 26

C. Application for Variation

1. Major Variation

a. Change of ownership

b. Additional product line

c. Transfer of location

d. Change of activity

Center for Drug Regulation and Research 27

C. Application for Variation

2. Minor Variation-Prior Approval

a. Change of business name

b. Zonal Change

Center for Drug Regulation and Research 28

C. Application for Variation

3. Minor Variation-Notification

a. Change of Pharmacist or other Qualified Personnel

b. Deletion of Activity

Center for Drug Regulation and Research 29

C. Application for Variation

Other changes – notified to FDA

Other variations may be added

Transfer of location – initial fee

Other variations – existing fee

Center for Drug Regulation and Research 30

D. Accessibility Forms – available at the FDA website

Center for Drug Regulation and Research 31

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 32

EXEMPTION IN PROVIDING ANOTHER PHARMACIST FOR

ADDITIONAL LICENSED ACTIVITY

Manufacturer Regulation

Exemption Exemption for Drug Manufacturer-Repacker and Drug Manufacturer-Trader pharmacist to handle another non-manufacturing activity except retailing provided the ff conditions are met

1. Activities belong only to one establishment (single business entity with same name registration and ownership)

Center for Drug Regulation and Research 33

Exemption Exemption for Drug Manufacturer-Repacker and Drug Manufacturer-Trader pharmacist to handle another non-manufacturing activity except retailing provided the ff conditions are met

2. Activities are confined only in one office/warehouse within the same premises

Center for Drug Regulation and Research 34

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 35

RESPONSIBILITIES OF IMPLEMENTING OFFICES

Manufacturer Regulation

FDA and Regional offices

May call on the assistance of any department office and/or government agency for the effective implementation of its rules and regulations

Center for Drug Regulation and Research 36

LGUs Enjoined in monitoring licensed

establishments

Report to FDA any violative establishments

Center for Drug Regulation and Research 37

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 38

TRANSITORY PROVISIONS

Manufacturer Regulation

Transitory Provision Submitted upon renewal for existing establishments

RMP

GPS Coordinates

Center for Drug Regulation and Research 39

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 40

REPEALING/ SEPARABILITY CLAUSE

Manufacturer Regulation

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 41

EFFECTIVITY

Manufacturer Regulation

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 42

ANNEX A

Manufacturer Regulation

Initial LTO Application 1. Application Form

2. Proof of Business Name Registration

3. Credentials of Pharmacist and other Qualified Personnel

4. Risk Management Plan

5. Location Plan

6. Site Master File

7. Proof of Payment

8. Self-Assessment Toolkit

Center for Drug Regulation and Research 43

Renewal LTO Application

1. Application Form

2. Copy of Certifications issued as a result of LTO Variation

3. Proof of Payment (e.g., Official receipt or Landbank On-Coll payment slip)

4. Self-Assessment Toolkit

Center for Drug Regulation and Research 44

Reissuance of Lost or Destroyed LTO

1. Letter of Request

2. Affidavit of Loss or Destruction

3. Proof of Payment

Center for Drug Regulation and Research 45

Voluntary Cancellation 1. Letter of Request

2. Original LTO

Center for Drug Regulation and Research 46

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 47

ANNEX B

Manufacturer Regulation

Change of Ownership

Center for Drug Regulation and Research 48

C change of ownership of the drug establishment

D

1. Letter of Request for Change

2. Application Form

3. Proof of business name registration reflecting the

new of owner

4. Deed of sale or transfer of rights of ownership

5. Proof of payment

6. Self-Assessment Toolkit

Additional Production Line

Center for Drug Regulation and Research 49

C Additional production line inside the manufacturer

D

1. Letter of Request for Change

2. Application Form

3. Updated Site Master File

4. Proof of payment

5. Self-Assessment Toolkit

Transfer of Location

Center for Drug Regulation and Research 50

C 1. Physical transfer of the drug establishment

2. Other variations (change of personnel, business

name) may also be included as long as the variation

is noted in the letter of request and the unique

requirements from the additional changes are

included. The fees remain the same as initial fee,

regardless of the additional variation.

Transfer of Location

Center for Drug Regulation and Research 51

D 1. Letter of Request for Change

2. Application Form

3. Proof of business name registration reflecting the

new address

4. New Location Plan

5. Updated Site Master File

6. Proof of payment

7. Self-Assessment Toolkit

Change of Activity

Center for Drug Regulation and Research 52

C 1. Additional activity engaged by the manufacturer (e.g. LTO as

Manufacturer-Repacker with additional activity as

Manufacturer)

2. Change from the initially licensed activity (e.g. LTO as

Manufacturer-Repacker to Manufacturer-Packer).

D

1. Letter of Request for Change

2. Application Form

3. Updated Site Master File

4. Proof of payment

5. Self-Assessment Toolkit

Change of Business Name

Center for Drug Regulation and Research 53

C 1. Change only in the business name

2. No transfer of location or change of ownership.

D

1. Letter of Request for Change

2. Application Form

3. Proof of business name registration reflecting the

new name of the business/drug establishment

4. Proof of payment

5. Self-Assessment Toolkit

Zonal Change

Center for Drug Regulation and Research 54

C change of the name/number of the street/building

without physical transfer of the establishment.

D

1. Letter of Request for Change

2. Application Form

3. Document issued by the local municipality as proof of

zonal change

4. Proof of payment

5. Self-Assessment Toolkit

Change of Pharmacist or Other Qualified Personnel

Center for Drug Regulation and Research 55

C 1. There is a change of the identified pharmacist

and/or other qualified personnel

2. For multiple pharmacists employed, the identified

responsible pharmacist that will be

replaced/changed shall be required to apply for

variation; the same goes for the other qualified

personnel

Change of Pharmacist or Other Qualified Personnel

Center for Drug Regulation and Research 56

D 1. Letter of Request for Change

2. Application Form

3. Credentials of the pharmacist and/or other

qualified personnel

4. Proof of payment

5. Self-Assessment Toolkit

Deletion of Activity

Center for Drug Regulation and Research 57

C deletion of any approved/added manufacturing

activity

D

1. Letter of Request for Change

2. Application Form

3. Termination of contract or conformance letter

4. Proof of payment

5. Self-Assessment Toolkit

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 58

Situation 1

MMZ Manufacturing, Inc. with an existing and valid LTO (CDRR-RIV-DM-123) wishes to transfer their ownership rights to ESM Laboratories, Inc. due to financial crisis.

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 59

Situation 2:

Company ABC holds an existing and valid LTO (CDRR-RIII-DM-001) as Repacker located at 401 Industrial Park, San Vicente, Bulacan. Since the business is doing well, the said company wants to venture manufacturing of its own product.

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 60

Situation 3:

JST Pharmaceuticals, a well-known manufacturer of generic medicines currently located at No. 5 Saint. James St., Brgy.,Ilaya, Zone 4, Dasmariñas, Cavite will change its address to No. 5 Saint. James St., Brgy.,Ilaya, Zone 3, Dasmariñas, Cavite due to unavoidable circumstance mandated by municipality.

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 61

Situation 4:

Amethyst Labs. Corp., is a holder of a newly issued LTO as Drug Manufacturer located at Laguna. Expanding its business, the management decided to relocate to a bigger place and replace its business name to One World Laboratories while retaining the current owners. Due to these major changes, their Registered Pharmacist decided to leave.

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 62

Situation 5:

Company EFG is an existing manufacturing establishment with valid LTO located at Cavite and currently into processing of non-penicillin products. During the validity of LTO the company wants to widen its scope as a manufacturer and will try to engage in processing penicillin related products.

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 63

Situation 6:

Cigna Laboratories located in 706 Industrial Rd., San Miguel Bulacan has an existing LTO as Drug Manufacturer (CDRR-NCR-DM-101) with validity until 30 September 2014. Due to inavoidable circumstance, the pharmacist-in-charge filed her resignation.

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 64

Situation 7:

Leo Manufacturers currently owned by the Monreal Group of Companies has a valid and existing LTO as Packer-Repacker. Due to a controversy, its clients started to terminate their contracts. Due to this incident, to maximize the remaining resources and to cover up for their losses, the company decided to stop their repacking activity and would just remain as a packer.

Republic of the Philippines Department of Health

Food and Drug Administration

Center for Drug Regulation and Research 65